Earlier this year, the pharmaceutical arm of Fosun International, a Chinese company with a market cap of over 13 billion USD, announced a1.3 billion USD buyout of India based Gland Pharma.
Chinese companies are increasingly making healthcare deals abroad in order to become relevant and active players in the global healthcare market. The domestic market provides limited opportunities for Chinese companies to develop innovative healthcare products. Investing in healthcare ventures overseas allows Chinese investors to not only access vital expertise and technology, but also expand their reach into more innovation-friendly markets.
According to Nick Stephens, Senior Associate at Boston Healthcare Associates, Chinese healthcare companies are “more akin to global equity investors rather than multinational pharmaceutical companies”.
He points out that “For an innovative biopharmaceutical manufacturer, right now China is hardly the most attractive first market to launch” a new product, due to slow-moving government agencies and bureaucratic red tape.
Chinese investors who are planning to make significant deployments in the global healthcare market often turn to trusted facilitators to source high-potential opportunities. Naseba has spent over a decade building close relationships with investors around the world, including China. Our analysts conduct daily phone calls with Chinese investors, and fully understand their needs and mandates.
On December 7th, 2016, in Shanghai, Naseba will be hosting the Chinese Healthcare Investment Meeting to introduce pre-screened Chinese investors to pre-qualified healthcare investment opportunities from around the world.
Submit your business case:
Oops! We could not locate your form.
To learn more, contact:
Naseba investor introduction
+971 4 455 7954